Receptor tyrosine kinases as targets for anticancer drugs
- 1 January 2002
- journal article
- review article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 8 (1), 17-23
- https://doi.org/10.1016/s1471-4914(01)02217-1
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinomaLung Cancer, 2000
- Epidermal Growth Factor Receptor Signal TransactivationIUBMB Life, 2000
- FGF Receptor Mutations: Dimerization Syndromes, Cell Growth Suppression, and Animal ModelsIUBMB Life, 2000
- Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteinesOncogene, 1998
- Ret in human development and oncogenesisBioEssays, 1997
- Signal transduction by receptors with tyrosine kinase activityCell, 1990
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial originNature, 1985
- Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cellsNature, 1984